An enhanced workflow for variant interpretation in UniProtKB/Swiss-Prot improves consistency and reuse in ClinVar. by Famiglietti, M.L. et al.
© The Author(s) 2019. Published by Oxford University Press. Page 1 of 8
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
(page number not for citation purposes)
Database, 2018, 1–8
doi: 10.1093/database/baz040
Original article
Original article
An enhanced workﬂow for variant interpretation
in UniProtKB/Swiss-Prot improves consistency
and reuse in ClinVar
M.L. Famiglietti 1,*, A. Estreicher 1, L. Breuza 1, S. Poux 1,
N. Redaschi 1, I. Xenarios 2, A. Bridge 1 and the UniProt
Consortium1,3,4,5
1Swiss-Prot Group, SIB Swiss Institute of Bioinformatics, CMU, 1 rue Michel Servet, 1211 Geneva 4,
Switzerland, 2University of Lausanne, 1015 Lausanne, Switzerland, 3European Molecular Biology Lab-
oratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge
CB10 1SD, UK, 4Protein Information Resource, Georgetown University Medical Center, 3300 Whitehaven
Street NW, Suite 1200, WA 20007, USA and 5Protein Information Resource, University of Delaware, 15
Innovation Way, Suite 205, Newark DE 19711, USA
*Corresponding author. Tel.: (+41 22) 379 49 18; Fax: (+41 22) 379 58 58; Email: livia.famiglietti@sib.swiss
Citation details: Famiglietti,M.L., Estreicher,A., Breuza,L. et al. An enhanced workﬂow for variant interpretation in
UniProtKB/Swiss-Prot improves consistency and reuse in ClinVar. Database (2019) Vol. 2019: article ID baz040;
doi:10.1093/database/baz040
Received 29 October 2018; Revised 7 January 2019; Accepted 7 March 2019
Abstract
Personalized genomic medicine depends on integrated analyses that combine genetic
and phenotypic data from individual patients with reference knowledge of the functional
and clinical signiﬁcance of sequence variants. Sources of this reference knowledge
include the ClinVar repository of human genetic variants, a community resource that
accepts submissions from external groups, and UniProtKB/Swiss-Prot, an expert-curated
resource of protein sequences and functional annotation. UniProtKB/Swiss-Prot provides
knowledge on the functional impact and clinical signiﬁcance of over 30 000 human
protein-coding sequence variants, curated frompeer-reviewed literature reports. Herewe
present a pilot study that lays the groundwork for the integration of curated knowledge
of protein sequence variation from UniProtKB/Swiss-Prot with ClinVar. We show that
existing interpretations of variant pathogenicity in UniProtKB/Swiss-Prot and ClinVar
are highly concordant, with 88% of variants that are common to the two resources
having interpretations of clinical signiﬁcance that agree. Re-curation of a subset of
UniProtKB/Swiss-Prot variants according to American College of Medical Genetics and
Genomics (ACMG) guidelines using ClinGen tools further increases this level of agree-
ment, mainly due to the reclassiﬁcation of supposedly pathogenic variants as benign,
based on newly available population frequency data. We have now incorporated ACMG
guidelines and ClinGen tools into the UniProt Knowledgebase (UniProtKB) curation
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workﬂow and routinely submit variant data from UniProtKB/Swiss-Prot to ClinVar. These
efforts will increase the usability and utilization of UniProtKB variant data and will
facilitate the continuing (re-)evaluation of clinical variant interpretations as data sets and
knowledge evolve.
Database URL: www.uniprot.org/
Introduction
The use of patient sequence data in personalized medicine
requires reference knowledge on the functional impact and
role of genetic variants in human disease. The development
of standardized guidelines for variant interpretation (1–4)
and freely available repositories of variant data such as
ClinVar (5), as well as efforts by ClinVar and ClinGen to
standardize the annotation of clinical variants (6, 7) (see
https://www.clinicalgenome.org/about/about-the-clingen-
and-clinvar-partnership/), has been a major factor in
improving the availability of reliable, high-quality genetic
variant data for researchers and clinicians. Resources such
as ExAC and gnomAD provide variant frequency data for
large population data sets that create a framework to re-
evaluate earlier pedigree studies and are another important
part of ongoing efforts to standardize and improve variant
interpretation (8).
UniProtKB/Swiss-Prot, the expert-curated section of the
UniProt Knowledgebase (UniProtKB), contains information
on over 30 000 variants linked to Mendelian diseases in
13 000 human protein sequence records (9, 10). The vari-
ant information from UniProtKB/Swiss-Prot, curated from
decades of peer-reviewed literature, represents an important
resource for understanding the impact of protein sequence
variants. The additional context provided by curated infor-
mation on protein function, subcellular location, interac-
tions and sequence features, such as protein domains, active
sites and post-translational modifications, can also help
to inform the analysis of the role of sequence variants in
disease.
Here we present a pilot study that aims to facilitate the
reuse of curated variant data fromUniProtKB/Swiss-Prot by
ClinVar, thereby laying the groundwork for further integra-
tion of these two resources. We find that existing variant
annotations that are common to the two resources are
highly consistent and that consistency is further improved
by re-curation of UniProtKB/Swiss-Prot variants using Clin-
Gen tools for variant interpretation and guidelines pro-
vided by the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology
(ACMG-AMP, abbreviated here as ACMG) (2). Our work
confirms the feasibility and utility of incorporating ClinGen
guidelines and tools into the UniProtKB curation work-
flow, and we now routinely submit newly curated stan-
dardized interpretations of variant data from UniProtKB/
Swiss-Prot to ClinVar. This development will facilitate the
reuse and continuous (re-)evaluation of variant annota-
tions from UniProtKB/Swiss-Prot and other sources as new
knowledge becomes available.
Materials and methods
Identifying variants shared by
UniProtKB/Swiss-Prot and ClinVar and generation
of working sets for variant reinterpretation
ClinVar accepts variant interpretations from clinical testing
laboratories, research laboratories, locus-specific databases,
expert panels and other groups. Submissions that deal
with the same variant and variant–phenotype relations are
grouped in a single ClinVar record, which is assigned a
defined review status score. The scores and their meanings
are as follows: 0 star, interpretations by a single submit-
ter without any assertion criteria; 1 star, interpretations
by a single submitter with assertion criteria provided; 2
stars, concordant interpretations by multiple submitters
with assertion criteria provided; 3 stars, interpretations by
expert panels; and 4 stars, interpretations by clinical prac-
tice guideline-providing groups. In this work, we compared
UniProtKB/Swiss-Prot variant interpretations with those
from other submitters found in ClinVar records having 2-
star status.
Using UniProtKB and ClinVar releases of December
2017, we used common dbSNP identifiers and Human
Genome Variation Society (HGVS) names to identify 4 286
missense variants in UniProtKB/Swiss-Prot that were also
reported in the ClinVar records with 2-star status (Supple-
mentary Table S1).As ACMG guidelines are only applicable
to variants associatedwithMendelian diseases,we excluded
those variants found in multifactorial disorders.We selected
subsets of variants for re-curation randomly from this set of
4 286 common variants.
Deﬁning agreement in interpretations of clinical
signiﬁcance
ClinVar employs the 5-tier classification developed by
ACMG for variants associated with Mendelian dis-
eases; a specific variant may be classified as pathogenic,
likely pathogenic, benign, likely benign or of uncertain
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Table 1. Global comparison of the interpretations of 4286 variants common to UniProtKB/Swiss-Prot and ClinVar
Original classification in
UniProtKB/Swiss-Prot
Classification in ClinVar Total
P/LP B/LB VUS
Disease 1328 111 94 1533
Polymorphism 46 2328 128 2502
Unclassified 55 81 115 251
Total 1429 2520 337 4286
P/LP, pathogenic/likely pathogenic; B/LB, benign/likely benign; VUS, variant of uncertain significance. Diagonals represent concordant interpretations, off-diagonals discordant
interpretations.
significance with respect to a particular disease (2).
UniProtKB classifies variants associated with Mendelian
diseases as either disease (causing), polymorphism or
unclassified with respect to a particular disease (10).
We define equivalence between the two classification
schemes as follows: UniProtKB/Swiss-Prot interpretation
‘disease’ corresponds to ClinVar ‘pathogenic’ and ‘likely
pathogenic’, ‘polymorphism’ corresponds to ‘benign’ and
‘likely benign’ and ‘unclassified’ corresponds to ‘uncertain
significance’ (see http://www.uniprot.org/docs/humsavar).
Calculating concordance between interpretations
of clinical signiﬁcance
For a given category of variants, we define the percentage of
concordance betweenUniProtKB/Swiss-Prot andClinVar as
the number of interpretations common to both resources,
divided by the number of total interpretations in either
of the two resources, multiplied by 100. For instance,
concordance for variants interpreted as polymorphisms in
UniProtKB/Swiss-Prot (likely benign or benign in ClinVar)
is 100× (2328 / 2328+ 46+128+111+81) or 86% (see
Table 1).
Tools and variant interpretation procedure
We used the ClinGen pathogenicity calculator (11) to re-
curate UniProtKB/Swiss-Prot variants according to ACMG
guidelines. This tool allows users to enter evidence for a
specific variant–disease association with links to supporting
data. The tool assigns a default weighting to each evidence
(which can be modified if required) and combines evidences
to generate a report with the appropriate pathogenicity
assessment. Information on diseases, variants and func-
tional data was gathered from peer-reviewed publications
and other resources, including OMIM (12), Genetics Home
Reference (13), Orphanet (14), the Exome Aggregation
Consortium (ExAC release 0.3) and the genome Aggrega-
tion Database (gnomAD release 2.0) (8). Allele frequency
cutoffs (to evaluate variant frequency) were obtained from
ExAC. The maximum credible population allele frequency
was calculated using online tools (15) when disease preva-
lence information was available. Computational evidence
was taken into account if the predictions from PolyPhen
(16), SIFT (17) and MutationTaster (18) were concordant.
Results
Global comparison of variant interpretation
We first analyzed 4 286 interpretations of variant
pathogenicity common to UniProtKB/Swiss-Prot and
ClinVar 2-star records. We reasoned that comparison
of variants from UniProtKB/Swiss-Prot with the set of
ClinVar 2-star records—where multiple submitters agree
on the interpretation of clinical significance, but which
lack validation by expert panels—is likely to provide an
easily interpretable upper-bound estimate of the level of
disagreement between UniProtKB/Swiss-Prot and ClinVar.
A total of 3 771 interpretations of variant pathogenicity
assessments (88%) were found to be in agreement between
UniProtKB/Swiss-Prot and ClinVar 2-star records (Table 1;
a complete listing of all variant interpretations is provided
in Supplementary Table S1). Concordance was 86% for
variants interpreted as polymorphisms in UniProtKB/Swiss-
Prot (likely benign or benign in ClinVar), 81% for dis-
ease variants from UniProtKB/Swiss-Prot (likely pathogenic
or pathogenic in ClinVar) and only 24% for variants of
uncertain significance (see Table 1). Variants classified as
being of uncertain significance in either resource are over-
represented in the set of variants whose interpretations
disagree, possibly because the individual lines of evidence
about these variants are inconclusive in isolation and so
particularly susceptible to varying interpretation. We pro-
vide an example to illustrate this below.
The effect of re-curation on variant interpretation
between ClinVar and UniProtKB/Swiss-Prot
To investigate the effect of re-curation on the level of
agreement of variant interpretations in UniProtKB/Swiss-
Prot and ClinVar, we randomly selected two sets of variants
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Table 2. Re-curation of 100 UniProtKB variants with discordant interpretations compared to ClinVar
Original classification in
UniProtKB/Swiss-Prot
Classification following re-curation Total
P/LP B/LB VUS
Disease 1 31 20 52
Polymorphism 6 4 8 18
Unclassified 4 16 10 30
Total 11 51 38 100
P/LP, pathogenic/likely pathogenic; B/LB, benign/likely benign; VUS, variant of uncertain significance.
Table 3. Re-curation of 100 UniProtKB variants with concordant interpretations compared to ClinVar
Original classification in
UniProtKB/Swiss-Prot
Classification following re-curation Total
P / LP B / LB VUS
Disease 54 0 4 58
Polymorphism 0 38 0 38
Unclassified 0 0 4 4
Total 54 38 8 100
P/LP, pathogenic/likely pathogenic; B/LB, benign/likely benign; VUS, variant of uncertain significance.
where the interpretations of variant pathogenicity in
UniProtKB/Swiss-Prot and ClinVar either agreed (100
variants) or disagreed (100 variants). Each set was re-
curated using the ACMG guidelines and the ClinGen
pathogenicity calculator.
In the set of 100 discordant variants, we solved 78
conflicts, modified 7 interpretations without reaching
agreement with ClinVar and retained 15 of the existing
interpretations (Table 2). The most common change
observed upon re-curation of discordant variants was the
reclassification of pathogenic variants as benign variants or
variants of uncertain significance, due to the great majority
of cases to the use of population data.
In the set of 100 concordant variants, we confirmed
96 interpretations but modified the interpretation of 4
variants, introducing 4 new conflicts between the two
resources (Table 3). The most common change observed
upon re-curation of concordant variants was the reclas-
sification of pathogenic variants as variants of uncertain
significance.
The reduction in the number of variants interpreted
as ‘(likely) pathogenic’ and the increase of the number of
‘uncertain significance’ and ‘(likely) benign’ in both sets of
100 randomly selected variants are in line with the findings
of others (8, 19).
We describe below two representative examples from
this re-curation work. The first example illustrates how the
use of newly available population frequency data results in
the reclassification of a supposedly pathogenic variant as
‘likely benign’. The reclassification of pathogenic variants
as benign or likely benign is the most common change seen
upon re-curation in our study and is the main cause of
improved agreement in variant interpretations. The second
example illustrates how functional data can inform con-
sideration of population frequency data. In this particular
case, this leads to reclassification of a pathogenic variant
as being of ‘uncertain significance’ and creates a conflict
between UniProtKB/Swiss-Prot and ClinVar—which is rel-
atively common for variants of ‘uncertain significance’. This
highlights how only coordinated re-curation of interpreta-
tions of variant pathogenicity by multiple submitters will
allow the community to achieve agreement on these difficult
cases.
Example 1. Population frequency data support
reclassiﬁcation of a pathogenic variant in GLI3 as
likely benign, in agreement with ClinVar.
Transcriptional activator GLI3 (UniProtKB accession
P10071) mediates Hedgehog (Hh) signaling in embryogen-
esis and limb development (20). GLI3 pathogenic variants
cause non-syndromic and syndromic polydactyly, including
the rare autosomal dominant Greig cephalopolysyndactyly
syndrome (GCPS, OMIM accession 175700) (21, 22).
GCPS has an estimated prevalence of around 1 in 1 000 000
in the general population (23).
GLI3 variant p.Ile808Met (NM 000168.5:c.2424A>G;
ClinVar Variation ID 235210) was originally annotated
in UniProtKB/Swiss-Prot as a pathogenic variant causing
GCPS, based on small-scale pedigree studies (24) and
Database, Vol. 2019, Article ID baz040 Page 5 of 8
functional assays showing a deleterious effect of this variant
on nuclear localization and transcriptional activity (25).
Multiple submitters to ClinVar had annotated this variant
as ‘Benign’ or ‘Likely benign’ for GCPS based on the results
of clinical testing.
Re-curation of this variant in UniProtKB/Swiss-Prot led
to the resolution of this discrepancy; the variant was reclas-
sified as ‘Likely benign’ as the observed variant allele fre-
quencies (close to 0.2% in ExAC and gnomAD) are not
consistent with a pathogenic role in GCPS (which has a
much lower estimated prevalence in the population). The
ACMG guidelines recommend to ‘consider how closely a
functional assay reflects the biological environment’ when
using functional data for variant interpretation. We there-
fore chose in this case to disregard the previous functional
data on this variant due to the lack of a clear mechanis-
tic link between GLI3 functional impairment observed in
vitro and the disease. The precise ACMG criteria that are
relevant in this case include the following: ‘Allele frequency
is greater than expected for disorder’ (abbreviated to ‘BS1’)
and ‘Observed in a healthy adult individual for a recessive
(homozygous), dominant (heterozygous), or X-linked (hem-
izygous) disorder, with full penetrance expected at an early
age’ (‘BS2’). Both could be considered as ‘strong’ evidence
that this variant is benign, but we considered ‘BS2’ only as
‘supporting’ evidence as GCPS penetrance is not 100% (23).
Example 2. Conﬂicting functional and population
data support reclassiﬁcation of a pathogenic
variant in ATP7B as being of uncertain
signiﬁcance, creating a disagreement with
ClinVar.
ATP7B (UniProtKB accession P35670) is a transmembrane
ion transporter involved in cellular copper ion homeostasis
that is predominantly expressed in the liver (26). ATP7B
dysfunction causes Wilson disease (WD, OMIM accession
277900), an autosomal recessive disorder characterized
by decreased biliary excretion of copper, impaired copper
incorporation into ceruloplasmin (the major copper
carrying protein in the blood) and copper accumulation
in the liver, brain, kidney and eye. Disease penetrance is
incomplete, and clinical presentations are highly variable,
mainly consisting of hepatic and neurological symptoms.
WD prevalence is estimated to be 1/30 000 with a carrier
frequency of 1.1% (1/90) according to Genetics Home
Reference and the medical literature (27), although some
authors report a prevalence of 1/10 000 or higher as many
patients may remain undiagnosed (28, 29).
ATP7B variant p.Met645Arg (NM 000053.3:c.
1934T>G; ClinVar Variation ID 3862) was originally
interpreted as pathogenic in both UniProtKB/Swiss-Prot
and ClinVar. The interpretation in UniProtKB/Swiss-Prot
was based on published claims of pathogenicity and the
repeated identification of this variant in patients with
WD, often in a compound heterozygous state with a
pathogenic variant (27, 30–34). Other ClinVar submitters
have interpreted the clinical significance of this variant as
pathogenic, based on the results of clinical testing.
Re-curation of this variant in UniProtKB/Swiss-Prot
led us to reclassify this variant as of ‘uncertain signifi-
cance’ for WD due to conflicting population and func-
tional data, thereby creating a new discrepancy between
UniProtKB/Swiss-Prot and other ClinVar submitters.
Population data argue for a role for this variant in WD:
the overall frequency of p.Met645Arg is 0.05% in ExAC,
a value well below the known carrier frequency, and
no homozygote is reported in ExAC, nor in gnomAD.
However, copper transport activity of p.Met645Arg is
comparable to that of the wild-type protein (35, 36), and
the variant is also found in a compound heterozygous
state in a patient with hypoceruloplasminemia, devoid
of any clinical manifestations of WD and with normal
copper levels in Kupffer cells and hepatocytes (37). The
ClinGen pathogenicity calculator provides three distinct
and conflicting ACMG evidence types for these findings.
‘Absent from controls (or at extremely low frequency if
recessive) in Exome Sequencing Project, 1000 Genomes
Project, or Exome Aggregation Consortium’ (PM2), ‘For
recessive disorders, detected in trans with a pathogenic
variant’ (PM3) and ‘Well-established in vitro or in vivo
functional studies show no damaging effect on protein
function or splicing’ (BS3).
Discussion
Here we show that interpretations of the pathogenic sig-
nificance of human sequence variants are highly concor-
dant between UniProtKB/Swiss-Prot and ClinVar,with 88%
of interpretations agreeing. Our re-curation work using
ACMG guidelines and ClinGen tools suggests that agree-
ment could be expected to improve even further, probably
to around 94% for all UniProtKB/Swiss-Prot variants found
in ClinVar. Re-curation leads to a decrease in the proportion
of UniProtKB/Swiss-Prot classified as ‘pathogenic’, which
is due mainly to the use of newly available population
frequency data from resources such as ExAC and gnomAD.
These resources provide much deeper coverage of human
sequence variation than the small-scale pedigree analyses
on which many of the original interpretations were based.
Other studies that analyzed ClinVar submissions from mul-
tiple independent clinical laboratories have reported similar
findings (7, 38).
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The ACMG guidelines and the ClinGen pathogeni-
city calculator provide a framework for consistent curation
that serves to focus curator judgment, but curator judgment
remains essential to choose and appropriately weight
ACMG-based evidences, as illustrated by the two cases
presented here. GLI3 is a transcriptional activator mediat-
ing Hh signaling in embryogenesis and limb development.
Experimental assays performed in vitro suggest that GLI3
variant p.Ile808Met reduces GLI3 transcriptional activity
to some degree, but there is no information on the effect
on ‘Hh’ signaling. Available data do not meet the ACMG
recommendations for the use of functional evidence.
Published guidelines also recommend the consideration of
functional information as an auxiliary support to genetic
data (1, 2), and very strong population data indicates
that this variant is benign with respect to GCPS. We
therefore chose to disregard the available in vitro assay
data for the purposes of assessing this variant, as this
would have introduced unfounded uncertainty about the
role of this variant in this disease. This contrasts with how
functional data was used in our reinterpretation of the role
of ATP7B variant p.Met645Arg in WD. Here, convincing
experimental data using a variety of assays find no effect of
p.Met645Arg on ATP7B copper transport activity in vitro
or in vivo. These findings affect consideration of genetic
evidence, where allele frequency is compatible with a role
in disease. One explanation for this apparent discrepancy
in genetic and functional data could be that ATP7B variant
p.Met645Arg is in linkage disequilibrium with an as yet
unidentified pathogenic variant defining a complex allele.
In this scenario, variant p.Met645Arg would be recurrently
detected in WD patients but would exhibit no functional
effect when tested in isolation.
We could not solve all conflicts between the subset of
UniProtKB/Swiss-Prot variants analyzed here and variants
in ClinVar, but we do not expect to be able to achieve
complete agreement without working together with other
ClinVar submitters. Yang et al. (38) found that most sub-
mitters agreed on around 90% of variant classifications
and that in general one or more outliers (mostly research
and curation groups) provided a different interpretation
from the rest. Variants of uncertain significance are highly
represented among the set of variants with interpretations
that disagree in UniProtKB/Swiss-Prot and ClinVar. One
source of these discrepancies could be in the way groups use
functional data, as illustrated by the case of ATP7B variant
p.Met645Arg, where functional and population data seem
to say different things about the possible role of this variant
in disease.Groups that do not consider functional data from
the literature will classify this variant differently from those
who do, and for whom there is more doubt about its role,
while the weight given to functional evidence also strongly
influences variant interpretation. Others have also found
that the use of functional data is a major source of persistent
differences in variant interpretation between groups (7).
Another source of possible inconsistency is the use by
clinical laboratories of private data and guidelines (par-
ticularly for specific diseases) that differ from the general
guidelines of ACMG [e.g. (39)]. Even when interpretations
are unanimous, they may not necessarily be correct, and
systematic review by experts using multiple evidence types
(functional and genetic) is likely to be the best guarantee of
accurate assessments of pathogenicity. In this setting, the
role of the biocurator may be to draw expert attention
to conflicting evidence and variant interpretations that
deserve re-examination by clinicians, as in the case of
21 genes implicated in Brugada syndrome, of which 20 were
reclassified as disputed with regard to any assertions of a
pathogenic role by a clinical domain expert panel (40).
Efforts to standardize variant interpretations using
shared guidelines and tools promote interoperability and
data sharing between resources.We have now incorporated
ACMGguidelines and the ClinGen pathogenicity calculator
in our daily curation workflow for UniProtKB/Swiss-
Prot and routinely submit our interpretations of variant
pathogenicity to ClinVar. We will continue to re-curate
existing variant interpretations in UniProtKB/Swiss-Prot,
particularly variants whose interpretations in UniProtKB/
Swiss-Prot differ from those found in ClinVar, as well
as curating newly discovered variants. We expect that
these efforts will facilitate the reuse of our data and
increase the already high degree of concordance between
UniProtKB/Swiss-Prot and ClinVar.
With the increasing amount of variation data generated
by massive widespread genome sequencing, the scientific
community is just at the beginning of a huge effort to
understand the role of genetic variants in health and disease.
While discerning only the tip of the iceberg, one may hear
the philosopher saying ‘I know that I know nothing’.
Links
UniProtKB: https://www.uniprot.org
Humsavar: https://www.uniprot.org/docs/humsavar
Allele frequency calculator:
http://cardiodb.org/allelefrequencyapp
ClinGen: https://www.clinicalgenome.org
ClinGen pathogenicity calculator:
https://calculator.clinicalgenome.org/site/cg-calculator
ClinVar: https://www.ncbi.nlm.nih.gov/clinvar
ExAC: http://exac.broadinstitute.org
Genetics Home Reference: https://ghr.nlm.nih.gov
gnomAD: http://gnomad.broadinstitute.org
OMIM: https://www.omim.org
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Orphanet:
https://www.orpha.net/consor/cgi-bin/index.php
Submissions to ClinVar made in the course of this work can
be found at https://www.ncbi.nlm.nih.gov/clinvar?term=
SIB[Submitter].
Supplementary data
Supplementary data are available at Database Online.
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